ArticleTurk patoloji dergisi2026
Assessment of ROS1 Gene Rearrangement in Non-Small Cell Lung Cancer: Concordance Between ROS1 SP384 Immunohistochemistry and ROS1 FISH Assay in a Single Center in Türkiye.
Article in Turk patoloji dergisi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLung cancer is the most prevalent malignancy among men and women in Türkiye. National guidelines have been established to standardize molecular pathology diagnoses for the detection of driver mutations in non-small cell lung cancer with impact in the management and treatment of the disease. This study examines ROS1 gene alterations comparing immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) diagnostic techniques in a single-center cohort. MATERIAL AND
methodsA total of 200 biopsy specimens, including tissue and cytology samples from Ege University Hospital and external consultations (2019-2022), diagnosed with non-small cell lung cancer (NSCLC) were analyzed. ROS1 SP384 IHC staining patterns (H-Score) and reflex molecular testing for EGFR, ALK, and ROS1 were recorded.
resultsAmong 34 ROS1 IHC-positive cases (16.9%), ROS1 FISH positivity was observed in 7 cases (3.5%), including 5 IHC-positive (5/34; 14.7%) and 2 IHC-negative (2/166; 1.2%). The median H-Score of FISH-positive cases was 60.
conclusionROS1 IHC exhibited staining in cases harboring ALK, EGFR, and KRAS mutations, including one case with concurrent EGFR and ROS1 alterations. The ROS1 SP384 clone demonstrated 71.43% sensitivity and 84.97% specificity, with a negative predictive value of 99.3%. ROS1 IHC is a valuable screening modality for molecular alterations. FISH validation is recommended, and discordant cases may require NGS or RT-PCR for rare mutations or unidentified fusion partners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.